These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31168026)

  • 1. Cardio-renal safety of non-steroidal anti-inflammatory drugs.
    Radi ZA; Khan KN
    J Toxicol Sci; 2019; 44(6):373-391. PubMed ID: 31168026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.
    Rao P; Knaus EE
    J Pharm Pharm Sci; 2008 Sep; 11(2):81s-110s. PubMed ID: 19203472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.
    Mitchell JA; Warner TD
    Nat Rev Drug Discov; 2006 Jan; 5(1):75-86. PubMed ID: 16485347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.
    Walker C; Biasucci LM
    Postgrad Med; 2018 Jan; 130(1):55-71. PubMed ID: 29202670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of Adverse Effects Associated with Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitor].
    Masuda R
    Masui; 2016 Aug; 65(7):709-717. PubMed ID: 30358302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
    Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
    Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal adverse effects of nonsteroidal anti-inflammatory drugs.
    Harirforoosh S; Jamali F
    Expert Opin Drug Saf; 2009 Nov; 8(6):669-81. PubMed ID: 19832117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process.
    Vuolteenaho K; Moilanen T; Moilanen E
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):10-4. PubMed ID: 17973900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs.
    Ricciotti E; Castro C; Tang SY; Briggs WTE; West JA; Malik D; Rhoades SD; Meng H; Li X; Lahens NF; Sparks JA; Karlson EW; Weljie AM; Griffin JL; FitzGerald GA
    Circulation; 2018 Nov; 138(21):2367-2378. PubMed ID: 29930022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib.
    Urdaneta A; Siso A; Urdaneta B; Cardenas R; Quintero L; Avila R; Suarez-Roca H
    Brain Res Bull; 2009 Aug; 80(1-2):56-61. PubMed ID: 19463915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of COX-2 inhibitors.
    Sharma JN; Jawad NM
    ScientificWorldJournal; 2005 Aug; 5():629-45. PubMed ID: 16113940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective assessment of COX-1 and COX-2 selectivity of nonsteroidal anti-inflammatory drugs from clinical practice: use of genetic function approximation.
    Zambre AP; Ganure AL; Shinde DB; Kulkarni VM
    J Chem Inf Model; 2007; 47(2):635-43. PubMed ID: 17256838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study.
    Mastbergen SC; Jansen NW; Bijlsma JW; Lafeber FP
    Arthritis Res Ther; 2006; 8(1):R2. PubMed ID: 16356188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
    Giovanni G; Giovanni P
    J Nephrol; 2002; 15(5):480-8. PubMed ID: 12455713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.
    Harirforoosh S; Asghar W; Jamali F
    J Pharm Pharm Sci; 2013; 16(5):821-47. PubMed ID: 24393558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.